Bausch + Lomb Corporation
TSX:BLCO.TO · Toronto Stock Exchange
+$0.04 today
Vol 0.00M · Avg 0.00M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:BLCO.TO · Revenue to Net Income
Key Ratios
Analysis
$5.2B of revenue converted into -$218.8M of net income for the selected period. Gross margin is 54.9% and net margin is -4.2%, showing how much revenue survives after costs and taxes. EPS is $-0.62, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B +6.5% | $4.8B +15.6% | $4.1B +10.0% | $3.8B +0.1% | $3.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.3B +23.3% | $1.9B +14.0% | $1.6B +8.1% | $1.5B +3.5% | $1.5B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.8B -4.3% | $2.9B +16.6% | $2.5B +11.3% | $2.2B -2.1% | $2.3B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 54.8% -6.2pp | 60.9% +0.5pp | 60.4% +0.7pp | 59.7% -1.3pp | 61.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $371.0M +2.8% | $361.0M +11.4% | $324.0M +5.5% | $307.0M +13.3% | $271.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.2B +7.3% | $2.1B +19.9% | $1.7B +17.5% | $1.5B +6.4% | $1.4B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.9B +3.8% | $2.8B +16.1% | $2.4B +17.0% | $2.0B +3.9% | $2.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $421.0M -3.4% | $436.0M +14.1% | $382.0M +0.8% | $379.0M -8.7% | $415.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $609.0M +1.3% | $601.0M +20.4% | $499.0M -16.7% | $599.0M -18.3% | $733.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 11.9% -0.6pp | 12.5% +0.5pp | 12.0% -3.9pp | 15.9% -3.6pp | 19.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $188.0M +16.0% | $162.0M +24.6% | $130.0M -37.2% | $207.0M -37.1% | $329.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 3.7% +0.3pp | 3.4% +0.2pp | 3.1% -2.4pp | 5.5% -3.2pp | 8.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $12.0M -20.0% | $15.0M +0.0% | $15.0M +150.0% | $6.0M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $421.0M +5.5% | $399.0M +41.0% | $283.0M +93.8% | $146.0M | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$505.0M -27.5% | -$396.0M -33.8% | -$296.0M -120.9% | -$134.0M -1118.2% | -$11.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$317.0M -35.5% | -$234.0M -41.0% | -$166.0M -327.4% | $73.0M -77.0% | $318.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -6.2% -1.3pp | -4.9% -0.9pp | -4.0% -5.9pp | 1.9% -6.5pp | 8.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $35.0M -50.7% | $71.0M -13.4% | $82.0M +41.4% | $58.0M -53.6% | $125.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$360.0M -13.6% | -$317.0M -21.9% | -$260.0M -1833.3% | $15.0M -91.8% | $182.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -7.1% -0.4pp | -6.6% -0.3pp | -6.3% -6.7pp | 0.4% -4.4pp | 4.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -13.3% | -$1 -21.6% | -$1 -1824.9% | $0 -91.8% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -13.3% | -$1 -21.6% | -$1 -1829.0% | $0 -91.8% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $353.8M +0.5% | $351.9M +0.4% | $350.5M +0.1% | $350.0M +0.0% | $350.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $353.8M -0.0% | $353.9M +1.0% | $350.5M +0.1% | $350.2M +0.1% | $350.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Curaleaf Holdings, Inc.
TSX:CURA.TO
$3.12B
Trulieve Cannabis Corp.
TRUL.CN
$2.74B
Bausch Health Companies Inc.
TSX:BHC.TO
$2.51B
WELL Health Technologies Corp.
TSX:WELL.TO
$1.12B
Tilray Brands, Inc.
TSX:TLRY.TO
$801.35M
Spectral Medical Inc.
TSX:EDT.TO
$404.92M
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
$366.40M
Zentek Ltd.
ZEN.V
$66.14M
Sona Nanotech Inc.
SONA.CN
$32.60M
Ocumetics Technology Corp.
OTC.V
$30.63M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BLCO.TO generate?
Bausch + Lomb Corporation (BLCO.TO) reported $5.10B of revenue in fiscal 2025.
Is BLCO.TO profitable?
Bausch + Lomb Corporation (BLCO.TO) reported -$359,999,999.00 of net income, with a net margin of -7.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.